1. Therapeutic Approaches to the Management of EDS in OSA

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US and data that were published in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Nonpharmacologic Approaches to Addressing EDS

4. Pharmacologic Treatment of EDS

5. Caffeine

6. Amphetamines and Methylphenidate

7. Model for Promotion of Wakefulness by Modafinil and Armodafinil

8. Drugs With FDA Approval for EDS in OSA

9. Mechanism of Action of Pharmacologic Treatment of EDS

10. Solriamfetol 12-Week Trial Design

11. Solriamfetol 12-Week Trial Results: MWT

12. Solriamfetol 12-Week Trial Results: ESS

13. Solriamfetol 12-Week Trial Results: PGI-C Scale

14. Solriamfetol 12-Week Trial Results: FOSQ-10 Score

15. Solriamfetol 12-Week Trial Results: WPAI:SHP – Past 7 Days

16. Solriamfetol 12-Week Trial TEAEs

17. Solriamfetol 6-Week Trial Design

18. Solriamfetol 6-Week Trial Results

19. Pitolisant

20. Pitolisant in OSA

21. Concluding Remarks

22. Abbreviations

23. Abbreviations (cont)